Index
RUT
P/E
-
EPS (ttm)
-0.01
Insider Own
7.16%
Shs Outstand
166.22M
Perf Week
8.89%
Market Cap
1.10B
Forward P/E
18.13
EPS next Y
0.35
Insider Trans
-2.56%
Shs Float
160.09M
Perf Month
17.31%
Enterprise Value
1.25B
PEG
-
EPS next Q
0.00
Inst Own
58.75%
Perf Quarter
-14.04%
Income
0.55M
P/S
3.76
EPS this Y
3641.81%
Inst Trans
2.24%
Perf Half Y
-31.28%
Sales
291.85M
P/B
77.34
EPS next Y
192.86%
ROA
0.15%
Perf YTD
-18.85%
Book/sh
0.08
P/C
9.89
EPS next 5Y
-
ROE
-
52W High
10.08 -36.81%
Perf Year
54.99%
Cash/sh
0.64
P/FCF
39.33
EPS past 3/5Y
- -
ROIC
0.21%
52W Low
3.95 61.27%
Perf 3Y
168.78%
Dividend Est.
-
EV/EBITDA
33.13
Sales past 3/5Y
38.33% 70.20%
Gross Margin
81.70%
Volatility
3.45% 4.37%
Perf 5Y
62.92%
Dividend TTM
-
EV/Sales
4.27
EPS Y/Y TTM
99.47%
Oper. Margin
8.53%
ATR (14)
0.27
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
1.57
Sales Y/Y TTM
43.72%
Profit Margin
0.19%
RSI (14)
60.90
Dividend Gr. 3/5Y
- -
Current Ratio
2.19
EPS Q/Q
279.30%
SMA20
9.34%
Beta
0.81
Payout
0.00%
Debt/Eq
18.85
Sales Q/Q
42.78%
SMA50
4.29%
Rel Volume
0.69
Prev Close
6.12
Employees
435
LT Debt/Eq
18.40
SMA200
-9.08%
Avg Volume
1.80M
Price
6.37
IPO
Jun 21, 2018
Option/Short
Yes / Yes
Trades
Volume
1,242,658
Change
4.08%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-09-25 Initiated Barclays
Overweight
$9
Aug-12-25 Resumed H.C. Wainwright
Buy
$10
Nov-11-24 Downgrade Piper Sandler
Overweight → Neutral
$3
Mar-28-24 Initiated Oppenheimer
Outperform
$5
Aug-28-23 Initiated Craig Hallum
Buy
$4.50
Oct-21-22 Initiated Jefferies
Buy
$4
Apr-28-22 Initiated Craig Hallum
Buy
$6.50
Nov-17-21 Initiated SVB Leerink
Outperform
$6
Oct-29-21 Initiated H.C. Wainwright
Buy
$4
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$11
Feb-18-20 Initiated Piper Sandler
Overweight
$12
Jul-16-18 Initiated RBC Capital Mkts
Outperform
$24
Jul-16-18 Initiated Leerink Partners
Outperform
$24
Jul-16-18 Initiated Jefferies
Buy
$23
Show Previous Ratings
Apr-03-26 04:15PM
Mar-02-26 04:01PM
12:33PM
10:37AM
09:30AM
08:06AM
Loading…
08:06AM
07:13AM
(Associated Press Finance)
07:00AM
Feb-27-26 12:29PM
Feb-26-26 05:55PM
12:15PM
09:15AM
05:35AM
Feb-17-26 07:30AM
Jan-08-26 07:00AM
04:15PM
Loading…
Jan-02-26 04:15PM
Dec-31-25 07:09PM
Dec-18-25 01:13PM
Dec-01-25 07:00AM
Nov-06-25 09:30AM
08:30AM
07:00AM
Oct-30-25 06:45PM
Oct-23-25 07:30AM
Oct-20-25 12:00PM
09:15AM
Oct-16-25 09:06AM
Oct-13-25 07:58AM
Oct-03-25 04:15PM
12:00PM
09:15AM
Loading…
09:15AM
Sep-09-25 12:00PM
Aug-29-25 05:09AM
Aug-25-25 07:00AM
Aug-12-25 12:00PM
09:15AM
Aug-07-25 10:30AM
(Associated Press Finance)
+20.22%
09:30AM
08:35AM
07:32AM
(Associated Press Finance)
07:00AM
Jul-31-25 07:30AM
Jul-03-25 08:19AM
Jun-03-25 07:30AM
May-20-25 07:30AM
May-12-25 03:54PM
May-09-25 03:21AM
May-08-25 08:20AM
07:17AM
(Associated Press Finance)
07:00AM
May-07-25 12:08PM
11:51AM
May-05-25 05:30PM
May-01-25 07:00AM
Apr-22-25 06:46PM
Apr-17-25 07:00AM
Mar-28-25 08:00AM
Mar-27-25 10:18AM
Mar-20-25 10:13AM
Mar-19-25 04:49PM
Mar-17-25 08:00AM
Mar-07-25 02:08AM
Mar-06-25 09:30AM
08:15AM
07:22AM
(Associated Press Finance)
07:00AM
Feb-27-25 07:00AM
Feb-26-25 10:00AM
Feb-24-25 08:00AM
Feb-05-25 08:00AM
Jan-21-25 09:00AM
Jan-11-25 07:27AM
Jan-10-25 07:00AM
Jan-06-25 04:15PM
Nov-26-24 07:00AM
Nov-09-24 02:06AM
Nov-08-24 09:30AM
08:10AM
07:10AM
(Associated Press Finance)
07:00AM
Oct-31-24 08:00AM
Oct-04-24 04:05PM
Aug-22-24 07:00AM
Aug-08-24 08:25AM
07:30AM
(Associated Press Finance)
07:00AM
Aug-01-24 10:01AM
Jul-25-24 07:00AM
Jul-24-24 09:55AM
Jul-08-24 07:00AM
Jul-03-24 01:05PM
Jun-03-24 07:00AM
May-30-24 07:30AM
07:00AM
May-10-24 03:21PM
12:36PM
12:27AM
(Thomson Reuters StreetEvents)
May-09-24 11:55AM
08:10AM
07:11AM
(Associated Press Finance)
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hecht Beth See Remarks Apr 01 '26 Sale 5.99 16,667 99,859 1,209,840 Apr 03 05:45 PM Brady James Aloysius Director Mar 30 '26 Sale 5.54 10,834 60,036 89,166 Apr 01 05:54 PM JAMES BRADY Director Mar 30 '26 Proposed Sale 5.40 10,834 58,504 Mar 30 05:31 PM McCulloch Kevin See Remarks Mar 12 '26 Option Exercise 4.09 48,898 199,992 1,777,725 Mar 16 06:11 PM Pieper Steven See Remarks Mar 05 '26 Option Exercise 4.71 41,927 197,308 1,408,940 Mar 05 07:18 PM Hecht Beth See Remarks Mar 02 '26 Sale 6.25 16,667 104,086 1,226,507 Mar 04 05:28 PM BETH HECHT Officer Mar 02 '26 Proposed Sale 6.12 66,668 408,008 Mar 02 04:36 PM Hecht Beth See Remarks Feb 02 '26 Sale 7.45 16,667 124,147 1,243,174 Feb 02 06:11 PM McCulloch Kevin See Remarks Jan 08 '26 Sale 8.00 15,000 120,000 1,685,426 Jan 09 05:34 PM KEVIN MCCULLOCH Officer Jan 08 '26 Proposed Sale 7.21 60,000 432,600 Jan 08 04:22 PM Shannon John Patrick Jr See Remarks Jan 05 '26 Option Exercise 1.63 92,301 149,998 2,797,647 Jan 06 06:14 PM Shannon John Patrick Jr See Remarks Jan 05 '26 Sale 7.08 24,907 176,257 2,705,346 Jan 06 06:14 PM Hecht Beth See Remarks Jan 02 '26 Sale 7.43 16,667 123,776 1,308,103 Jan 05 06:01 PM JOHN H JOHNSON Director Dec 19 '25 Proposed Sale 7.22 135,402 977,034 Dec 19 06:15 PM JOHNSON JOHN Director Dec 19 '25 Sale 7.22 135,400 977,019 698,083 Dec 19 05:17 PM BORMANN-KENNEDY BARBARA-JEAN A Director Dec 12 '25 Sale 7.09 15,000 106,414 142,500 Dec 15 05:24 PM BARBARA-JEAN A BORMANN-KENNEDY Director Dec 12 '25 Proposed Sale 7.01 15,000 105,150 Dec 12 04:20 PM Hecht Beth See Remarks Dec 01 '25 Sale 7.01 16,667 116,781 1,320,176 Dec 02 05:14 PM Shannon John Patrick Jr See Remarks Nov 14 '25 Option Exercise 1.55 87,100 135,005 2,730,253 Nov 17 05:58 PM Shannon John Patrick Jr See Remarks Nov 13 '25 Option Exercise 1.55 8,970 13,904 2,666,395 Nov 17 05:58 PM Shannon John Patrick Jr See Remarks Nov 13 '25 Sale 7.46 23,242 173,402 2,643,153 Nov 17 05:58 PM Hecht Beth See Remarks Nov 11 '25 Sale 7.40 16,667 123,296 1,336,843 Nov 13 06:59 PM JOHN SHANNON Director Nov 13 '25 Proposed Sale 7.59 48,149 365,451 Nov 13 04:25 PM BETH HECHT Officer Nov 11 '25 Proposed Sale 7.72 66,668 514,677 Nov 12 07:02 AM PERSKY MARLA Director Sep 11 '25 Sale 7.72 15,500 119,610 142,000 Sep 12 05:09 PM MARLA PERSKY Director Sep 11 '25 Proposed Sale 7.81 15,500 121,055 Sep 11 04:24 PM SHERMAN JEFFREY W Director Aug 28 '25 Option Exercise 6.66 47,040 313,286 261,420 Aug 29 05:21 PM SHERMAN JEFFREY W Director Aug 28 '25 Sale 7.92 42,232 334,515 219,188 Aug 29 05:21 PM JEFFREY SHERMAN Director Aug 28 '25 Proposed Sale 7.92 42,232 334,511 Aug 28 04:09 PM JOHNSON JOHN Director Aug 13 '25 Sale 7.32 107,500 786,459 833,483 Aug 15 04:57 PM HALKUFF DAWN Director Aug 12 '25 Sale 7.28 42,500 309,226 115,000 Aug 13 04:47 PM JOHN H JOHNSON Director Aug 13 '25 Proposed Sale 7.32 107,500 786,452 Aug 13 04:08 PM DAWN HALKUFF Director Aug 12 '25 Proposed Sale 7.28 42,500 309,226 Aug 12 04:23 PM McCulloch Kevin See Remarks Jun 13 '25 Buy 4.38 25,000 109,475 1,708,585 Jun 16 04:26 PM Fairley Ricki Louise Director May 09 '25 Proposed Sale 4.90 56,667 277,668 May 09 05:28 PM
